Endothelial cells (ECs) apoptosis induced by oxidized low-density lipoprotein (ox-LDL
INTRODUCTION
Atherosclerosis is the lesion primarily underlies coronary artery disease and cerebrovascular disease, two of the most common causes of illness and death worldwide (1) . By virtue of their location between the blood and tissues and the multiple functions, the endothelial cells (ECs) play a major role in securing body homeostasis (2) . Under pathological conditions, endothelial dysfunction is a driving force in the initiation and development of atherosclerosis (3) . Apoptosis is one of the central mechanisms leading to endothelial dysfunction and results in inflammatory cell infiltration, lipid transport and neointima formation. These alterations induce atherosclerotic lesion rupture and later clinical complications (4) (5) (6) . Therefore, inhibiting ECs apoptosis is a promising novel therapeutic option against atherosclerosis. Although the development of atherosclerosis appears to be the result of multiple maladaptive pathways, a particularly important risk factor in the pathogenesis of atherosclerosis is oxidized low-density lipoprotein (ox-LDL), which contributes to endothelial apoptosis (7) . Early studies revealed that the morphological changes of cultured ECs exposed to ox-LDL are similar to those observed in the endothelium covering atherosclerotic lesions (8) . It has been further shown that ox-LDL induced apoptosis in ECs has been associated with the down-regulation of the anti-apoptotic protein Bcl-xl (9, 10) , which decreases the ratio of Bcl-xl:Bax and thereby initiating the mitochondria-dependent apoptotic pathway (11) . The Caspases, especially Caspase-3, are known to act downstream of Bcl-xl:Bax and play a key role in the execution of apoptosis (12) . The activity of Caspase-3 would give an index to the process of apoptosis (13) . MicroRNAs (miRNAs) are a family of highly conserved, small noncoding RNAs that posttranscriptionally repress gene expression via degradation or translational inhibition of their target mRNAs. There is mounting evidence suggesting that miRNAs are involved in nearly all physiological and pathological processes (14, 15) . Early studies have revealed a significant role of miRNAs in ECs inflammation (16) , proliferation (17) , migration (18) , senescence (19) , and apoptosis (20) . Among apoptomirs, let-7 is a prototype of human miRNA and was first identified in 2001 (21) . Let-7, down-regulated in several malignancies, regulates apoptosis via directly targeting oncogenes Ras, Myc, HMGA2, CDC25A, and CDK6 (22) . Microarray analysis performed on human umbilical vein endothelial cells (HUVECs) exposed to ox-LDL has shown that let-7c is one of the significantly up-regulated miRNAs, indicating that let-7c may be involved in ox-LDL-elicited ECs apoptosis and atherosclerosis-related processes (23) . To test this hypothesis, we used the ox-LDL-stimulated HUVECs as a model to investigate the possible role of let-7c in atherosclerotic process in ECs.
RESULTS

Let-7c was up-regulated in apoptotic HUVECs induced by ox-LDL
To analyze the kinetics of let-7c expression in ECs apoptosis induced by ox-LDL, HUVECs were exposed to ox-LDL for different http://bmbreports.org BMB Reports HUVECs were transfected with let-7c mimics or inhibitor, and let-7c levels were measured by qRT-PCR. (B) HUVECs were exposed to ox-LDL (50 μg/ml) for 48 h, or transfected with let-7c mimics or miR mimics control, or transfected with let-7c inhibitor or miR inhibitor control and further exposed to ox-LDL (50 μg/ml) for an additional 48 h. Bcl-xl protein was measured by western blot, and the β-actin expression was used for protein level normalization. (C) Let-7c does not affect Bcl-xl mRNA. HUVEC were transfected with let-7c mimics or miR mimics control, or let-7c inhibitor or miR inhibitor control, and Bcl-xl mRNA was measured by qRT-PCR. Bcl-xl mRNA expression was not changed by let-7c mimics and let-7c inhibitor. Values are means ± S.D. (n = 3). *P ＜ 0.05 compared with control group, **P ＜ 0.01 compared with control group. lengths of time. ECs apoptosis was detected by Annexin V-FITC/ propidium iodide (PI) double stain and let-7c expression was quantified by qRT-PCR. As shown in Fig. 1A and 1B, incubation of HUVECs with 50 μg/ml ox-LDL for 0 to 48 h resulted in a time-dependent induction of apoptotic cell death. With the increasing apoptotic rate, let-7c was gradually up-regulated after ox-LDL stimulation, and a more than 3-fold increase in the let-7c amount was observed at 48 h (Fig. 1C ).
Bcl-xl is one of the target genes for let-7c in HUVECs
Recently, the let-7 family of miRNAs was demonstrated to potentiate apoptosis in human hepatocellular carcinoma by inhibiting Bcl-xl (24) . Bcl-xl is one of the anti-apoptotic members of the Bcl-2 family and decreased in ECs apoptosis mediated by various stimuli (25) . In order to elucidate the relationship between let-7c and Bcl-xl in HUVECs, we manipulated let-7c level in HUVECs by transfecting with let-7c mimics or let-7c inhibitor. When 50 nM let-7c mimics was transfected into HUVECs, the level of let-7c increased up to 11.5-fold. In contrast, transfection of let-7c inhibitor decreased let-7c level by 64% ( Fig. 2A ). These data suggest that transfection of let-7c mimics or let-7c inhibitor can significantly alter let-7c level in HUVECs. Ox-LDL treatment decreased Bcl-xl level by 59% compared to control (Fig. 2B left) . Furthermore, over-expression of http://bmbreports.org let-7c in HUVECs reduced Bcl-xl protein expression by 38% (Fig.  2B middle) . In the contrast, Bcl-xl expression was increased in ox-LDL treated HUVECs after let-7c inhibitor transfection (Fig. 2B  right) . Although transfection of let-7c mimics or let-7c inhibitor changed Bcl-xl protein levels, transfection did not change Bcl-xl mRNA expression (Fig. 2C) . These results suggest that let-7c regulates Bcl-xl in a posttranscriptional manner in HUVECs.
To examine whether let-7c directly binds the 3'UTR of Bcl-xl mRNA, we constructed the luciferase reporter plasmid pMIR-Bclxl-3'UTR containing the putative let-7c binding site of Bcl-xl 3'UTR downstream of the luciferase open reading frame (Fig. 3A) . The pMIR-Bcl-xl-3'UTR construct was transfected into HUVECs together with let-7c inhibitor or miRNA inhibitor control. When let-7c inhibitor was cotransfected with pMIR-Bcl-xl-3'UTR, the expression of firefly luciferase was significantly increased compared to the miRNA inhibitor control cotransfected group (Fig. 3B) . We also generated a pMIR-Bcl-xl-3'UTR mutant with a single base mutation in the seed region of the putative binding sequence to investigate whether the up-regulation of firefly luciferase can be attributed to the mutation (Fig. 3A) . A single base mutation blocked the up-regulation of firefly luciferase induced by let-7c inhibitor, which strongly suggests a direct inhibitory effect of let-7c on Bcl-xl expression (Fig. 3B ).
Let-7c modulates apoptosis in HUVECs
To investigate the role of let-7c in ECs apoptosis, we transfected HUVECs with let-7c miRNAs and then subjected them to ox-LDL treatment. Caspase-3 activity assay and flow cytometry (FCM) http://bmbreports.org BMB Reports were used to analyze changes in apoptosis. As a result, ox-LDL stimulation increased Caspase-3 activity by nearly 6.5 fold in HUVECs (Fig. 4A left) , whereas the let-7c inhibitor transfection significantly decreased the Caspase-3 activity (Fig. 4A right) . Moreover, the activation of Caspase-3 was more intense in let-7c mimics-transfected HUVECs than in miRNA mimics control-transfected HUVECs (Fig. 4A middle) . Double stain of Annexin V-FITC/PI showed apoptotic rate was up-regulated in the presence of ox-LDL ( Fig. 4B and 4C left) . But this effect was attenuated when introducing let-7c inhibitor into ox-LDL-stimulated HUVECs ( Fig.  4B and 4C right) . On the other hand, let-7c mimics transfection increased apoptosis of HUVECs by nearly two-fold, compared to miRNA mimics control ( Fig. 4B and 4C middle) . Together, the let-7c over-expression and inhibition data suggest that let-7c contributes to apoptotic effect of ox-LDL in HUVECs.
DISCUSSION
Accumulating evidence suggests that some specific miRNAs play an important role in vascular diseases through regulating ECs behaviors. MiR-424 and miR-17-92 cluster have been identified as pro-angiogenic miRNAs (26, 27) . In contrast, miR-221 and miR-222 inhibited ECs migration, proliferation, and angiogenesis (17, 28) . The contribution of miR-155, miR-31, and miR-126 to vascular inflammation and diseases has also been documented (29) . Thus, the identification of miRNAs and their respective targets may offer new therapeutic strategies to treat vascular diseases including atherosclerosis. In the present study, we found that let-7c increasing during ox-LDL induced ECs apoptosis regulated levels of anti-apoptotic protein Bcl-xl. Endothelial apoptosis induced by ox-LDL is an initiative stage of atherosclerosis. We previously utilized a miRNA microarray to analyze the miRNA expression profile in ox-LDL-induced apoptotic HUVECs. We found that 4 miRNAs (miR-142-3p, miR-1207-3p, miR-365 and let-7c) were up-regulated after ox-LDL treatment, and inhibition of miR-365 could partly alleviate apoptotic cell death induced by ox-LDL via regulating the expression of Bcl-2 (23). The preliminary results gave an important indication of miRNAs associated with atherosclerosis, and changes in ECs expression induced by miR-365 were just one part of the mechanism responsible for ox-LDL-induced changes in ECs apoptosis. So we continue to assess other miRNAs involved in modulating ECs apoptosis. Among these up-regulated miRNAs, let-7c is known to be involved in the regulation of apoptosis (30) . The ubiquitously expressed let-7 family was one of the first mammalian miRNAs to be identified. The let-7 family is comprised of 12 family members (let-7-a1, a2, a3, b, c, d, e, f1, f2, g, i and miR-98) located on 8 different chromosomes (31) . In studies of various human cancers including lung, colon, ovarian, gastric cancer, leiomyoma and melanoma, let-7 family members have been described to be downregulated and exert pro-apoptotic effect during cancer progression. Further mechanism researches reveal that let-7 targets include cell cycle regulators such as CDC25A and CDK6, promoters of growth including RAS and c-myc and a number of early embryonic genes including HMGA2, Mlin-41 and IMP-1 (32). Shimizu et al. very recently showed that let-7 miRNAs down-regulated in human hepatoma cells and tissues directly target anti-apoptotic protein Bcl-xl and enhance apoptosis in cooperation with an anti-cancer drug targeting Mcl-1 in hepatocellular carcinoma (24) . In this study, we also investigated the expression of let-7c in ox-LDL-stimulated HUVECs. Consistent with the microarray result, our qRT-PCR assay revealed that let-7c expression was significantly up-regulated during HUVECs apoptosis, indicating that let-7c acts as a pro-apoptotic miRNA in this process. The Bcl-2 protein family was discovered by analysis of the t (14-18) chromosome translocation breakpoint in B-cell follicular lymphoma. Bcl-xl, one of the anti-apoptotic members of the Bcl-2 family, is critically involved in the mitochondrial pathway of apoptosis (33) . Bcl-xl blocks diverse apoptotic stimuli via inhibiting cytochrome-c release, maintaining mitochondrial membrane potential, inhibiting the production of reactive oxygen species, heterodimerizing with pro-apoptotic molecules and attenuating pro-apoptotic Bid (34) . Previous studies demonstrated that Bcl-xl was down-regulated in ECs apoptosis induced by Ang II (11), endostatin (35), hypoxia (36) and hypoxia/reoxygenation (25) . To the contrary, over-expression of Bcl-xl was able to protect ECs from apoptosis mediated by DNA damaging agent and pro-inflammatory cytokines (37) . Identifying the factors that regulate Bcl-xl levels is of paramount importance for better maintaining ECs viability and developing more effective therapies for atherosclerosis. In this study, we found let-7c over-expression induced the down-modulation of Bcl-xl protein but not of Bcl-xl mRNA, and let-7c blocking by let-7c inhibitor prevented Bcl-xl down-modulation induced by ox-LDL. Further luciferase reporter assay analysis demonstrated the Bcl-xl gene is one of the direct targets of let-7c in ECs. As Bcl-xl is closely related to cell apoptosis, we therefore explore the effect of let-7c on ox-LDL-mediated ECs apoptosis. As a result, let-7c over-expression enhanced ECs apoptosis whereas inhibition of let-7c could partly alleviate apoptotic cell death induced by ox-LDL, indicating let-7c promotes apoptosis in ox-LDL-treated HUVECs through attenuating Bcl-xl expression. These results suggest that let-7c high expression in ox-LDL-induced endothelial apoptosis may become a new biomarker in atherosclerosis. However, we must consider the discrepancy between in vitro and in vivo performance of let-7c. Multiple parameters, such as changes in expression in tissue, secretion of miRNA by cells, stability of miRNA molecule and interaction with other miRNAs may influence let-7c behavior in vivo. So, studies utilizing animal models of atherosclerosis and human atherosclerotic plaque samples are required to elucidate the in vivo effect of let-7c on endothelial apoptosis and atherosclerosis. Moreover, we only tested let-7c expression and its effect on apoptosis in HUVECs. We should further test other cell-lines which are not related with atherosclerotic process to know whether let-7c activation is specific in atherosclerosis.
In conclusion, we found the miRNA let-7c negatively regulates anti-apoptotic gene Bcl-xl expression in HUVECs. Transfection of let-7c inhibitor partially protects HUVECs from ox-LDL-induced apoptotic death. We believe that once the functional roles of miRNAs have been further clarified, they will become suitable therapeutic targets in endothelial apoptosis and atherosclerosis.
MATERIALS AND METHODS
Cell culture
HUVECs were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA) and 100 ug/ml penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA).
Ox-LDL preparation
Human ox-LDL was isolated from fresh human plasma by sequential ultracentrifugation, as described previously (40).
FCM analysis of apoptosis
HUVECs were cultured in 6-well plates and exposed to ox-LDL (50 μg/ml) for 0, 12, 24, and 48 h. Cells were harvested and stained with the Annexin V-FITC Apoptosis Detection Kit (Beyotime, Jiangsu, China). The number of cells undergoing apoptosis was determined by FCM.
MiRNA quantitative real-time PCR (qRT-PCR)
To quantify the expression of let-7c, we synthesized cDNA from 10 ng of RNA sample using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, CA, USA). Quantitative PCR was performed with TaqMan MicroRNA Assays (Applied Biosystems, CA, USA) specific for let-7c in a 7900HT RT-PCR machine (Applied Biosystems, CA, USA) according to the manufacturer's protocol.
Transfections with miRNAs
The let-7c mimics and let-7c inhibitor (Ribo Bio, Guangzhou, China) were transfected into HUVECs at a final concentration of 50 nM using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in six-well plates according to the manufacturer's instructions.
Western blot and mRNA qRT-PCR analysis
HUVECs were lysed and the protein extracts were denatured. The solubilized proteins (20 μg) were subjected to electrophoresis, blotted to polyvinylidene difluoride membrane, and reacted with specific antibodies. Primary antibodies against Bcl-xl and β-actin were from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and the secondary antibody was from KPL (Gaithersburg, MD, USA). Bcl-xl mRNA levels were analyzed using the SYBR Ⓡ Premix Ex Taq TM II kits (TaKaRa, Dalian, China) with gene specific primers on a Applied Biosystems 7900HT RT-PCR system, according to the manufacturer's instructions.
Luciferase assay
A 1,510-bp fragment of Bcl-xl 3'-UTR containing the putative miRNA target was PCR-amplified using human Bcl-xl cDNA as the template. The PCR product was gel purified and subcloned into the SpeIHindIII site of pMIR-REPORT Luciferase vector (Ambion), we also generate a pMIR-Bcl-xl-3'UTR mutant with a single base in the putative binding site. For luciferase assay, HUVECs were cotransfected with 100 ng of pMIR-Bcl-xl-3'UTR or pMIR-Bcl-xl-3'UTR mutant plasmid, and 50 nM of miRNA inhibitor control or let-7c inhibitor combined with lipofectamine 2000. After 48 h incubation, the cells were washed and lysed. The relative luciferase activity was assayed using the Promega Dual-Luciferase reporter assay system.
Measurement of apoptosis by Caspase-3 activity assay and FCM after transfection
HUVECs were transfected with miRNA control, let-7c mimics or let-7c inhibitor for 24 h and then exposed to ox-LDL (50 μg/ml) for an additional 48 h. After that, protein extracts were prepared and Caspase-3 activity was measured using Caspase-3 Activity Assay kit (Beyotime Institute of Biotechnology, Nantong, Jiangsu, China) according to the manufacturer's instructions. After transfection and ox-LDL treatment, HUVECs were collected and a quantitative measurement of apoptosis was determined by FCM as described previously.
Statistical analysis
Data are presented as mean ± S.D. and evaluated by analysis of variance (AVOVA) or student t-test when appropriate. Significance was established at a level of P ＜ 0.05.
